Surgical Outcomes Of Rhegmatogenous Retinal Detachment In Young Adults Ages 18–30 Years

Abstract

Purpose

The purpose of this study is to investigate associations with and surgical outcomes of rhegmatogenous retinal detachment (RRD) in young adults.

Methods

This is a retrospective consecutive case series of patients aged 18–30 years who underwent surgical repair for RRD between January 1, 2014 and December 1, 2016 at a university referral center.

Results

The current study includes 38 eyes with RRD. Documented high or moderate myopia was present in 28 (74%) eyes. Connective tissue disease was present in 3 (8%) eyes. Median pre-operative visual acuity (VA) was 20/70. Surgery was performed via scleral buckle (SB) alone in 27/38 (71%) and via combined SB and pars plana vitrectomy (SB/PPV) in 11/38 (29%) eyes. Single surgery anatomical success (SSAS) rate was 20/27 (74%) for SB and 7/11 (64%) for SB/PPV. The retina was reattached at last follow-up in 25/27 (93%) for SB and 11/11 (100%) for SB/PPV. The median postoperative VA was 20/40.

Conclusion

In the current study of young adults with RRD, the most common association was high or moderate myopia. Visual and anatomic outcomes at last follow-up were generally favorable.

Keywords:

• myopia
• rhegmatogenous retinal detachment
• RRD
• young adults

Acknowledgment

The abstract of this paper was presented in July 2019 at the American Society of Retina Specialists (ASRS) annual meeting as a poster presentation with interim findings. The poster’s abstract was published in “Posters” in the ASRS website: https://www.docwirenews.com/conference-coverage/asrs2019/surgical-outcomes-of-rhegmatogenous-retinal-detachment-in-young-adults/. The abstract of this paper was presented in September 2018 at the Retina Society annual meeting as a podium presentation with interim findings.

Disclosure

Thomas A Albini reports personal fees from Genentech, personal fees from Allergan, personal fees from Novartis, personal fees from Eyepoint, personal fees from Clearside, personal fees from Santen, personal fees from Bausch + Lomb, outside the submitted work. Jayanth Sridhar reports personal fees from Alcon, personal fees from Alimera Science, personal fees from Thrombogenics, outside the submitted work. Harry W Flynn Jr reports grants from National Institutes of Health (NIH), Bethesda, Maryland, during the conduct of the study. The authors report no other conflicts of interest in this work.